Despite the continued discovery of novel peptides for the treatment and prevention of human disease, many applications suffer because the optimal delivery technology remains a key missing link. Trinity is developing technology capable of transporting proteins, peptides and other macromolecules across intact mucosal barriers using endogenous epithelial cell pathways. This technology not only overcomes current limitations associated with protein and peptide transport, but also provides targeted delivery to specific cells of the body.
Trinity’s technology involves the production of recombinant protein chimeras comprised of:
| |
A “vehicle”;
for targeting and delivery -- a non-toxic form of Pseudomonas exotoxin
A, combined with
A “payload”; a desired protein / peptide
|
The chimeras are efficiently transported across the mucosae of the respiratory
tract, gastrointestinal tract and reproductive tract without damaging
the normal barrier properties of these tissues.
